Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.37 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.37 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2060597 | 0.83 | KDM4E (0.70) | KDM4EALDH1A1LMNAMAPTGAA | |
| SCHEMBL108376 | 0.83 | KDM4E (1.00) | KDM4EALDH1A1LMNAMAPTGAA | |
| SCHEMBL29502911 | 0.83 | KDM4E (1.00) | KDM4EALDH1A1LMNAMAPTGAA | |
| SCHEMBL34463681 | 0.81 | KDM4E (0.68) | KDM4EALDH1A1LMNAMAPTGAA | |
| SCHEMBL20670887 | 0.81 | KDM4E (0.47) | KDM4EALDH1A1SMN1; SMN2F2TSHR | |
| SCHEMBL15214028 | 0.81 | KDM4E (0.47) | KDM4EALDH1A1LMNASMN1; SMN2TSHR | |
| SCHEMBL12934033 | 0.80 | KDM4E (0.47) | KDM4ESMN1; SMN2 | |
| SCHEMBL25360449 | 0.79 | KDM4E (0.46) | KDM4EALDH1A1MAPTSMN1; SMN2GAA | |
| SCHEMBL20670573 | 0.79 | KDM4E (0.46) | KDM4EALDH1A1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL31481672 | 0.79 | KDM4E (0.46) | KDM4EALDH1A1MAPTSMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9169198-B2 | Method for the production of 2-amino-5-cyano-N,3-dimethylbenzamide | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-10-27 | — | — | US | disclosed |
| US-20140148611-A1 | METHOD FOR THE PRODUCTION OF 2-AMINO-5-CYANO-N,3-DIMETHYLBENZAMIDE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-29 | — | — | US | disclosed |
| US-8420821-B2 | Process for production of 4-oxoquinoline compound | JAPAN TOBACCO INC. (JP) | 2013-04-16 | — | — | US | disclosed |
| US-8383819-B2 | Method for producing 4-oxoquinoline compound | JAPAN TOBACCO INC. (JP) | 2013-02-26 | — | — | US | disclosed |
| US-7863308-B2 | Substituted thiophenes | AUSPEX PHARMACEUTICALS, INC. (US) | 2011-01-04 | — | — | US | disclosed |
| US-20100280086-A1 | SUBSTITUTED THIOPHENES | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100240904-A1 | PROCESSES FOR THE PREPARATION OF N-(2-ACETYL-4,6-DIMETHYLPHENYL)-3--2-THIOPHENECARBOXAMIDE | PFIZER INC | 2010-09-23 | — | — | US | disclosed |
| US-20100240904-A1 | PROCESSES FOR THE PREPARATION OF N-(2-ACETYL-4,6-DIMETHYLPHENYL)-3--2-THIOPHENECARBOXAMIDE | PFIZER INC | 2010-09-23 | — | — | US | disclosed |
| US-7754892-B2 | Processes for the preparation of N-(2-acetyl-4,6-dimethylphenyl)-3-{[(3,4 dimethyl-5-isoxazolyl)amino]sulfonyl}-2-thiophenecarboxamide | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-7754892-B2 | Processes for the preparation of N-(2-acetyl-4,6-dimethylphenyl)-3-{[(3,4 dimethyl-5-isoxazolyl)amino]sulfonyl}-2-thiophenecarboxamide | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-6683103-B2 | SULFONAMIDES CONTAINING OXAZOLE AND SUBSTITUTED THIOPHENE RINGS, USEFUL FOR TREATING HYPERTENSION, CARDIOVASCULAR DISEASE, ASTHMA, PULMONARY HYPERTENSION, INFLAMMATORY DISEASES, VISION DEFECTS, MENSTRUAL DISORDERS, RENAL FAILURE | TEXAS BIOTECHNOLOGY CORPORATION | 2004-01-27 | — | — | US | disclosed |
| CN-1414965-A | Sulfonamides and derivatives thereof that modulate the activeity of endothelin | TEXAS BIOTECHNOLOGY CORP (US) | 2003-04-30 | — | — | CN | disclosed |
| EP-1244657-A2 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2002-10-02 | — | — | EP | disclosed |
| US-6432994-B1 | CARDIOVASCULAR DISORDERS, GLAUCOMA; ANTIINFLAMMATORY, WOUND HEALING, HYPOTENSIVE, ANTIASTHMATIC, AND ANTIANAPHYLACTIC AGENTS | TEXAS BIOTECHNOLOGY CORPORATION | 2002-08-13 | — | — | US | disclosed |
| US-20020091270-A1 | Sulfonamides for treatment of endothelin-mediated disorders | ENCYSIVE PHARMACEUTICALS INC. | 2002-07-11 | — | — | US | disclosed |
| US-20010056183-A1 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | TEXAS BIOTECHNOLOGY CORPORATION | 2001-12-27 | — | — | US | disclosed |
| WO-2001049685-A2 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2001-07-12 | — | — | WO | disclosed |
| WO-2001049289-A1 | PHARMACEUTICAL AND VETERINARY USES OF ENDOTHELIN ANTAGONISTS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2001-07-12 | — | — | WO | disclosed |
| EP-0980369-A1 | SULFONAMIDES FOR TREATMENT OF ENDOTHELIN-MEDIATED DISORDERS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2000-02-23 | — | — | EP | disclosed |
| WO-1998049162-A1 | SULFONAMIDES FOR TREATMENT OF ENDOTHELIN-MEDIATED DISORDERS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1998-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148611-A1 | METHOD FOR THE PRODUCTION OF 2-AMINO-5-CYANO-N,3-DIMETHYLBENZAMIDE | ALKBH5, ALKBH2, MMAB | KDM4E 124/4885ALDH1A1 1505/4885LMNA 1696/4885 |
| US-20020091270-A1 | Sulfonamides for treatment of endothelin-mediated disorders | EDNRA, ECE1, EDNRB | KDM4E 1188/4885ALDH1A1 4657/4885LMNA 1866/4885 |
| US-20100280086-A1 | SUBSTITUTED THIOPHENES | EDNRB, ECE1, EDNRA | KDM4E 1620/4885ALDH1A1 1056/4885LMNA 3120/4885 |
| US-20010056183-A1 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | EDNRA, EDNRB, ECE1 | KDM4E 2262/4885ALDH1A1 4647/4885LMNA 3671/4885 |
| US-20100240904-A1 | PROCESSES FOR THE PREPARATION OF N-(2-ACETYL-4,6-DIMETHYLPHENYL)-3--2-THIOPHENECARBOXAMIDE | EDNRB, EDNRA, ECE2 | KDM4E 722/4885ALDH1A1 3714/4885LMNA 1460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.